What is the ticker symbol for Surface Oncology?

Surface Oncology trades under the ticker SURF on NASDAQ.

What sector does Surface Oncology operate in?

Surface Oncology is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze SURF in a portfolio?

PortView shows SURF's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

Surface Oncology (SURF) Stock Analysis

NASDAQHealthcareBiotechnology

$1.07-0.93%

1-year price historyRange $0.57 – $1.40

52-week range$1.07

$0.56$1.43

What Surface Oncology does

Surface Oncology, Inc. is a clinical-stage biotechnology firm focused on discovering and developing innovative immuno-oncology treatments for cancer patients in the United States. Its pipeline features a range of antibody-based therapeutics, including NZV930, a fully human IgG4 monoclonal antibody designed to modulate extracellular adenosine production, and SRF617, another human IgG4 monoclonal antibody that aims to block CD39's enzymatic activity, thereby influencing adenosine levels and ATP degradation. Other key candidates include SRF388, which targets interleukin 27; GSK4381562, an antibody aimed at CD112R, an inhibitory protein found on natural killer and T cells; and SRF114, which targets the chemokine receptor CCR8. The company also maintains strategic partnerships, holding a licensing agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited for the development, manufacturing, and commercialization of SRF813-targeting antibodies. Furthermore, it has a separate licensing deal with Vaccinex, Inc. concerning the development, production, and commercialization of antibodies targeting SRF114. Established in 2014, Surface Oncology, Inc. operates from its headquarters in Cambridge, Massachusetts.

Key metrics

Market cap

$65.08M

P/E (TTM)

-0.69

EPS (TTM)

$-1.56

Beta

1.75

Dividend yield

0.00%

Revenue / share

$0.54

50-day avg

$0.96

200-day avg

$0.82

52-week high

$1.43

52-week low

$0.56

CEO

Lisa McGrath

ETFs linked to SURF

Broad-market and Healthcare sector ETFs an investor holding Surface Oncology is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how SURF fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze SURF in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for Surface Oncology?: Surface Oncology trades under the ticker SURF on NASDAQ.
Which exchange is SURF listed on?: SURF is listed on NASDAQ.
What sector does Surface Oncology operate in?: Surface Oncology is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze SURF in a portfolio?: PortView shows SURF's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.